Search Result

Results for "

EED

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bcl-2 Family (1) BMI1 (1) Caspase (1) E1/E2/E3 Enzyme (2) E3 Ligase Ligand-Linker Conjugates (9) Endogenous Metabolite (1) Epigenetic Reader Domain (1) Histone Demethylase (1) Histone Methyltransferase (33) Ligands for Target Protein for PROTAC (3) PARP (1) PROTAC Linkers (3) PROTACs (10) Reference Standards (3) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (43) Cardiovascular Disease (2) Inflammation/Immunology (2) Neurological Disease (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101117

EED226 Maximum Cited Publications 15 Publications Verification	Histone Methyltransferase	Cancer
EED226 is a polycomb repressive complex 2 (PRC2) inhibitor, which binds to the K27me3-pocket on embryonic ectoderm development (EED) and shows strong antitumor activity in xenograft mice model . EED226 is a potent, selective, and orally bioavailable EED inhibitor . EED226 inhibits PRC2 with an IC₅₀ of 23.4 nM when the H3K27me0 peptide is used as a substrate in the in vitro enzymatic assays .

HY-158102

Rinzimetostat 1 Publications Verification ORIC-944	Histone Methyltransferase	Cancer
Rinzimetostat (ORIC-944) is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). Rinzimetostat is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer.

HY-103663

MAK683 4 Publications Verification	Histone Methyltransferase	Cancer
MAK683 is an embryonic ectoderm development (EED) inhibitor extracted from patent US20160176882 A1, compound example 2. MAK683 exhibits IC₅₀s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay .

HY-130708

UNC6852 4 Publications Verification	Histone Methyltransferase PROTACs	Cancer
UNC6852 is a selective polycomb repressive complex 2 (PRC2) degrader based on PROTAC and contains an *EED* (embryonic ectoderm development) ligand and a von Hippel-Lindau ligand, with an IC₅₀ of 247 nM for EED .

HY-139400

Pociredir 1 Publications Verification FTX-6058	Histone Methyltransferase	Cardiovascular Disease
Pociredir (FTX-6058) is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir can induce HbF protein expression in cell and murine models. Pociredir can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia .

HY-136977

EEDi-5285 1 Publications Verification	Histone Methyltransferase	Cancer
EEDi-5285 is an exceptionally potent and orally active embryonic ectoderm development (EED) inhibitor with an IC₅₀ value of 0.2 nM for binds to the EED protein. EEDi-5285 has anti-cancer activity .

HY-101512

A-395 4 Publications Verification	Histone Methyltransferase	Cancer
A-395, a chemical probe, is an antagonist of polycomb repressive complex 2 (PRC2) protein-protein interactions that potently inhibits the trimeric PRC2 complex (EZH2-EED-SUZ12) with an IC₅₀ of 18 nM .

HY-132922

EEDi-5273 APG-5918	Histone Methyltransferase	Cancer
EEDi-5273 (APG-5918) is a potent and orally active embryonic ectoderm development (EED) inhibitor with an IC₅₀ of 0.2 nM. EEDi-5273 can inhibit the polycomb repressive complex 2 (PRC2) activity and block trimethylation of histone H3 lysine 27. EEDi-5273 can be used for the research of cancer, such as ovarian cancer .

HY-130615

*PROTAC EED* degrader-2** 1 Publications Verification	PROTACs Histone Methyltransferase	Cancer
PROTAC EED degrader-2 is a von Hippel-Lindau-based PROTAC targeting *EED* with a pK_D of 9.27. PROTAC EED degrader-2 is a polycomb repressive complex 2 (PRC2) inhibitor (pIC₅₀=8.11) targeting the EED subunit .

HY-130979

EED226-COOH	Ligands for Target Protein for PROTAC Histone Methyltransferase	Cancer
EED226-COOH is an EED226-derived ligand for target protein *EED* ligand for PROTAC, binds to a ligand for VHL via linker to form UNC6852 (HY-130708) to degrade PRC2 .

HY-160924

MS147	PROTACs BMI1 E1/E2/E3 Enzyme Histone Methyltransferase	Cancer
MS147 is a VHL-based PROTAC degrader of BMI1 and RING1B (polycomb repressive complex 1 core components). MS147 directly binds EED and VHL E3 ligase, recruiting the ligase to the EED-BMI1/RING1B complex to induce time-dependent, ubiquitination-mediated degradation of BMI1 and RING1B. MS147 reduces histone H₂A Lys119 mono-ubiquitination without altering histone H₃ Lys27 tri-methylation and inhibits cancer cells proliferation. MS147 can be used for the research of cancer, such as chronic myelogenous leukemia and b-cell lymphoma .

HY-130815A

MAK683-C2-acid hydrochloride	Ligands for Target Protein for PROTAC Histone Methyltransferase	Cancer
MAK683-CH2CH2COOH binds to EED (embryonic ectoderm development protein). MAK683-CH2CH2COOH and a VHL ligand for the E3 ubiquitin ligase have been used to design PROTAC EED degrader-1 (HY-130614) and PROTAC EED degrader-2 (HY-130615) .

HY-W004697

Boc-GABA-OH	PROTAC Linkers	Cancer
Boc-GABA-OH is a PROTAC linker which can be used to synthesis UNC6852, an EED-targeted PROTAC .

HY-130614

*PROTAC EED* degrader-1**	PROTACs Histone Methyltransferase	Cancer
PROTAC EED degrader-1 is a von Hippel-Lindau-based PROTAC targeting *EED* with a pK_D of 9.02. PROTAC EED degrader-1 is a polycomb repressive complex 2 (PRC2) inhibitor (pIC₅₀=8.17) targeting the EED subunit .

HY-139400A

Pociredir hydrochloride 1 Publications Verification FTX-6058 hydrochloride	Histone Methyltransferase	Cardiovascular Disease
Pociredir (FTX-6058) hydrochloride is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir hydrochloride can induce HbF protein expression in cell and murine models. Pociredir hydrochloride can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia .

HY-158239

MS181	PROTACs E1/E2/E3 Enzyme	Cancer
MS181 (compound 1) is a potent cereblon (CRBN)-recruiting and EED-binding polycomb repressive complex 1 (PRC1) PROTAC degrader. MS181 decreases the expression of EED, EZH2, SUZ12, BMI1 and RING1B. MS181 shows antiproliferative activity (Strtucture Note: Red, EED binder (HY-158771); Blue, CRBN ligand (HY-41547); Black, Linker HY-131717) .

HY-W014099

Boc-NH-C4-acid	PROTAC Linkers	Cancer
Boc-NH-C4-acid is a PROTAC linker, which belongs to a Alkyl/ether linker. Boc-NH-C4-acid can be used in the synthesis of the compound PROTAC1, and specifically degrades EED, EZH2, and SUZ12 in the PRC2 Complex.

HY-158102A

Rinzimetostat TFA 1 Publications Verification ORIC-944 TFA	Histone Methyltransferase	Cancer
Rinzimetostat (ORIC-944) TFA is the TFA salt form of ORIC (HY-158102). Rinzimetostat TFA is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). Rinzimetostat TFA is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer .

HY-135045

(S,R,S)-AHPC-C4-COOH VH032-C4-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C4-COOH (VH032-C4-COOH) (linker 45) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-targeted PROTAC .

HY-RS04173

EED Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
EED Human Pre-designed siRNA Set A contains three designed siRNAs for EED gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EED Human Pre-designed siRNA Set A EED Human Pre-designed siRNA Set A

HY-103663A

MAK683 hydrochloride	Histone Methyltransferase	Cancer
MAK683 hydrochloride is an embryonic ectoderm development (EED) inhibitor extracted from patent US20160176882 A1, compound example 2. MAK683 exhibits IC₅₀s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay .

HY-130816

(S,R,S)-AHPC-O-Ph-PEG1-NH2 VH032-O-Ph-PEG1-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-O-Ph-PEG1-NH2 (VH032-O-Ph-PEG1-NH2) is E3 ligase ligand-linker conjugate and incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-O-Ph-PEG1-NH2 is used in PROTAC EED degrader-1 (HY-130614). PROTAC EED degrader-1 is a PROTAC targeting EED with a pK_D of 9.02 .

HY-130815

MAK683-CH2CH2COOH	Histone Methyltransferase Ligands for Target Protein for PROTAC	Cancer
MAK683-CH2CH2COOH binds to EED (embryonic ectoderm development protein). MAK683-CH2CH2COOH and a VHL ligand for the E3 ubiquitin ligase have been used to design PROTAC EED degrader-1 (HY-130614) and PROTAC EED degrader-2 (HY-130615) .

HY-114176B

(S,R,S)-AHPC-C4-NH2 dihydrochloride VH032-C4-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C4-NH2 dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC .

HY-174372

EZH2-IN-23	Histone Methyltransferase	Cancer
EZH2-IN-23 (Compound 25) is an EZH2 inhibitor that exhibits potent enzymatic inhibition of the PRC2 complex (EZH2, EED, SUZ12, AEBP2, RbAp48) with a biochemical IC₅₀ of 0.8 nM. EZH2-IN-23 inhibits H3K27 trimethylation in cellular assays, showing an IC₅₀ of 40 nM. EZH2-IN-23 displays good rat PKproperties with 100 % oral bioavailability.

HY-132970

EED ligand 1	Histone Methyltransferase	Cancer
EED ligand 1 is a diverse, potent, and efficacious inhibitor that target the EED subunit of the polycomb repressive complex 2 (PRC2) methyltransferase.

HY-P2266

SAH-EZH2	Histone Methyltransferase	Cancer
SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 .

HY-174397

EED-IN-3	Histone Methyltransferase Epigenetic Reader Domain	Cancer
EED-IN-3 is an orally active *EED* inhibitor. EED-IN-3 effectively inhibits PRC2 by binding to *EED* (IC₅₀ = 0.62 μM for EED) and downregulates H3K27me3. EED-IN-3 can efficiently and selectively inhibit PC3 cells with the _IC50 of 3.69 μΜ and could significantly suppress colony formation and migration. EED-IN-3 can be used for research on prostate cancer.

HY-178694

DC-PRC2in-01	Histone Methyltransferase	Cancer
DC-PRC2in-01 is a potent EZH2-EED interaction inhibitor with an IC₅₀ of 4.21 μM and a K_d of 4.56 μM. DC-PRC2in-01 disrupts the EZH2-EED interaction, leading to degradation of PRC2 core proteins and decrease of H3K27me3 levels, inhibition of PRC2-driven lymphoma cell proliferation, and cell cycle arrest. DC-PRC2in-01 can be used for the research of PRC2-related cancers, such as Diffuse Large B-cell Lymphoma (DLBCL) and follicular lymphoma (FL) .

HY-114176

(S,R,S)-AHPC-C4-NH2 hydrochloride VH032-C4-NH2 hydrochloride; VHL Ligand-Linker Conjugates 13; E3 ligase Ligand-Linker Conjugates 28	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC .

HY-114176A

(S,R,S)-AHPC-C4-NH2 VH032-C4-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC .

HY-148641

ZJH-16	Histone Methyltransferase	Cancer
ZJH-16 (Compound 11e) is an orally active *EED* inhibitor (IC₅₀ = 2.72 nM, K_d = 4.4 nM). ZJH-16 inhibits the growth of lymphoma cells and reduces H3K27 trimethylation levels. ZJH-16 inhibits tumor growth in lymphoma animal models. ZJH-16 can be used for research on lymphoma and other cancers .

HY-RS23097

Eed Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Eed Rat Pre-designed siRNA Set A contains three designed siRNAs for Eed gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Eed Rat Pre-designed siRNA Set A Eed Rat Pre-designed siRNA Set A

HY-130637

Boc-NH-PEG1-Ph-O-CH2COOH	PROTAC Linkers	Cancer
Boc-NH-PEG1-Ph-O-CH2COOH is a PROTAC Linker which is used for the EED-targeted PROTAC .

HY-130638

(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc VH032-O-Ph-PEG1-NH-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc (VH032-O-Ph-PEG1-NH-Boc) is a synthesized E3 ligase ligand-linker conjugate which is used for the EED-targeted PROTAC .

HY-101117R

EED226 (Standard)	Histone Methyltransferase Reference Standards	Cancer
EED226 (Standard) is the analytical standard of EED226 (HY-101117). This product is intended for research and analytical applications. EED226 is a polycomb repressive complex 2 (PRC2) inhibitor, which binds to the K27me3-pocket on embryonic ectoderm development (EED) and shows strong antitumor activity in xenograft mice model . EED226 is a potent, selective, and orally bioavailable EED inhibitor . EED226 inhibits PRC2 with an IC50 of 23.4 nM when the H3K27me0 peptide is used as a substrate in the in vitro enzymatic assays .

HY-182366

EED-IN-5	Histone Methyltransferase	Neurological Disease Inflammation/Immunology
EED-IN-5 is an orally active, EZH2-selective trisubstituted pyridine-based *EED-H3K27me3* inhibitor and immunomodulator with anti-inflammatory activity. The IC₅₀ value of EED-IN-5 against *EED* is 28.21 nM. In mouse models, EED-IN-5 preferentially and persistently accumulates in lymph nodes after oral administration. By reducing the H3K27me3 level of dendritic cells and inhibiting their migration, EED-IN-5 decreases the infiltration of specific dendritic cells, macrophages and T cells into the spinal cord and brain. EED-IN-5 exhibits hERG inhibitory activity, shows negative results in the Mini-Ames test, and causes no obvious toxicity upon long-term high-dose administration. EED-IN-5 can be used for the research of multiple sclerosis .

HY-101512D

rel-A-395 hydrochloride	Histone Methyltransferase	Cancer
rel-A-395 hydrochloride is the relative configuration of A-395 (HY-101512) hydrochloride. A-395 is an antagonist of polycomb repressive complex 2 (PRC2) protein-protein interactions that potently inhibits the trimeric PRC2 complex (EZH2-EED-SUZ12) with an IC₅₀ of 18 nM .

HY-130711

(S,R,S)-AHPC-C3-NH2 VH032-C3-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader .

HY-130711A

(S,R,S)-AHPC-C3-NH2 TFA VH032-C3-NH2 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C3-NH2 TFA (VH032-C3-NH2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader .

HY-130711C

(S,R,S)-AHPC-C3-NH2 dihydrochloride VH032-C3-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C3-NH2 (dihydrochloride) is the dihydrochloride form of (S,R,S)-AHPC-C3-NH2 (HY-130711). (S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader .

HY-182365

EED-IN-4	Histone Demethylase	Neurological Disease Inflammation/Immunology
EED-IN-4 is an orally active, EZH2-selective immunomodulator and *EED-H3K27me3* inhibitor (EED, IC₅₀=28.21 nM) with anti-inflammatory activity. In mouse models, EED-IN-4 preferentially and persistently accumulates in lymph nodes after oral administration. By reducing the H3K27me3 level of dendritic cells and inhibiting their migration, EED-IN-4 reduces the infiltration of immune cells into the central nervous system and effectively alleviates spinal cord inflammation. EED-IN-4 shows weak inhibitory activity against hERG channels and is non-mutagenic, with no obvious toxicity observed upon long-term oral administration. EED-IN-4 can be used for the research of multiple sclerosis .

HY-RS16662

Eed Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Eed Mouse Pre-designed siRNA Set A contains three designed siRNAs for Eed gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Eed Mouse Pre-designed siRNA Set A Eed Mouse Pre-designed siRNA Set A

HY-181320

PROTAC EZH2 Degrader-19	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-19 (compound 6) is a is a PROTAC protein degrader targeting EZH2 with an IC₅₀ of 15.00 nM. PROTAC EZH2 Degrader-19 induces strong degradation of all PRC2 subunits (EZH2, SUZ12, *EED, RbAp48*) in a concentration- and time-dependent manner.PROTAC EZH2 Degrader-19 exhibits antiproliferative effects in cancer cells.PROTAC EZH2 Degrader-19 can be used for the research of cancer .

HY-103663R

MAK683 (Standard)	Reference Standards Histone Methyltransferase	Cancer
MAK683 (Standard) is the analytical standard of MAK683 (HY-103663). This product is intended for research and analytical applications. MAK683 is an embryonic ectoderm development (EED) inhibitor extracted from patent US20160176882 A1, compound example 2. MAK683 exhibits IC₅₀s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay .

HY-181413

PROTAC EZH2 Degrader-44	PROTACs Histone Methyltransferase Bcl-2 Family Caspase PARP	Cancer
PROTAC EZH2 Degrader-44 (compound 60) is a highly efficient PROTAC degrader targeting the EZH2-PRC2 complex. By recruiting the CRBN E3 ligase and relying on the proteasome system, PROTAC EZH2 Degrader-44 simultaneously induces the degradation of core components EZH2, SUZ12 and *EED, thereby significantly reducing the levels of H3K27me3* and CARM1. PROTAC EZH2 Degrader-44 exerts antiproliferative effects through a dual mechanism: on the one hand, it triggers mitochondrial dysfunction leading to decreased membrane potential; on the other hand, it strongly promotes apoptosis by regulating Bcl-2 family proteins (upregulating Bax, Caspase-3 and PARP, and downregulating Bcl-2). PROTAC EZH2 Degrader-44 exhibits only extremely low cytotoxicity in human normal mammary epithelial, liver and kidney cells, showing a favorable safety window. PROTAC EZH2 Degrader-44 is an ideal tool molecule for exploring the mechanisms of targeted therapy for triple-negative breast cancer .

HY-101512R

A-395 (Standard)	Reference Standards Histone Methyltransferase	Cancer
A-395 (Standard) is the analytical standard of A-395 (HY-101512). This product is intended for research and analytical applications. A-395, a chemical probe, is an antagonist of polycomb repressive complex 2 (PRC2) protein-protein interactions that potently inhibits the trimeric PRC2 complex (EZH2-EED-SUZ12) with an IC50 of 18 nM .

HY-124660A

A-395N	Endogenous Metabolite	Others
A-395N serves as a control probe for A-395, a highly potent and selective chemical probe targeting the polycomb protein EED, a key player in Polycomb repressive complex 2 (PRC2) responsible for transcriptional repression via histone H3K27 methylation. While A-395N bears structural similarities to A-395, it demonstrates no pharmacological activity in biochemical or cellular assays, making it an ideal control compound.

HY-181392

PROTAC EZH2 Degrader-35	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-35 (compound U3i (44)) is a PROTAC protein degrader targeting EZH2 with a human EZH2 K_a of 16.19 nM. PROTAC EZH2 Degrader-35 exhibits antiproliferative activity in triple-negative breast cancer cells and minimal cytotoxicity in normal human epithelial, hepatic, renal cells.PROTAC EZH2 Degrader-35 can be used for the research of triple-negative breast cancer .

HY-181308

PROTAC EZH2 Degrader-13	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-13 is an EZH2-targeting PROTAC with an IC₅₀ of 2.70 nM. PROTAC EZH2 Degrader-13 exerts antiproliferative effects in cancer cells. PROTAC EZH2 Degrader-13 can be used for the research of cancer .

Cat. No.	Product Name	Target	Research Area

HY-P2266

SAH-EZH2	Histone Methyltransferase	Cancer
SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P74179

	EED Protein, Human (sf9, His-GST) EED; HEED; Polycomb protein EED; WAIT1	Human	Sf9 insect cells
	EED protein is a core member of the Polycomb group (PcG) and is critical in the PRC2/EED-EZH2 complex, driving "Lys-9" and "Lys-27" methylation on histone H3 to achieve transcriptional repression . It recognizes trimethylated "Lys-26" on histone H1 and inhibits the methyltransferase activity of the PRC2 complex on nucleosomal histone H3 "Lys-27". EED Protein, Human (sf9, His-GST) is the recombinant human-derived EED protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P89689

	EED Antibody (YA9033) Polycomb protein EED, hEED, Embryonic ectoderm development protein, WD protein associating with integrin cytoplasmic tails 1, WAIT-1, EED	WB, ICC/IF, IF-Tissue, IP, ELISA	human
	EED Antibody (YA9033) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to EED.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: